share_log

Virpax Pharmaceuticals | 8-K: VIRPAX PHARMACEUTICALS REPORTS 2024 SECOND QUARTER RESULTS AND RECENT DEVELOPMENTS

Virpax Pharmaceuticals | 8-K: VIRPAX PHARMACEUTICALS REPORTS 2024 SECOND QUARTER RESULTS AND RECENT DEVELOPMENTS

Virpax製藥 | 8-K:VIRPAX PHARMICALS公佈2024年第二季度業績和近期進展
美股SEC公告 ·  08/13 19:37

牛牛AI助理已提取核心訊息

Virpax Pharmaceuticals, Inc., a Delaware-based company specializing in non-addictive pain management and other pharmaceuticals, reported its financial results for the second quarter ended June 30, 2024, on August 13, 2024. The company announced a decrease in general and administrative expenses to $1.5 million from $1.9 million in the same period the previous year, attributed to reduced severance and insurance expenses. Research and development expenses increased to $2.0 million, up from $1.3 million, mainly due to preclinical activities for their lead asset, Probudur. The operating loss for the quarter was $3.5 million, compared to $3.1 million in 2023. As of June 30, 2024, Virpax had cash reserves of approximately $1.9 million. The company also highlighted recent developments, including positive results from a pharmacokinetics and safety study for Probudur, securing $2.8 million from warrant exercises, and regaining compliance with Nasdaq's minimum bid price requirement. Additionally, Virpax completed a $2.5 million secured loan financing, which led to a reorganization of the company's Board of Directors and the repayment of litigation settlement liabilities.
Virpax Pharmaceuticals, Inc., a Delaware-based company specializing in non-addictive pain management and other pharmaceuticals, reported its financial results for the second quarter ended June 30, 2024, on August 13, 2024. The company announced a decrease in general and administrative expenses to $1.5 million from $1.9 million in the same period the previous year, attributed to reduced severance and insurance expenses. Research and development expenses increased to $2.0 million, up from $1.3 million, mainly due to preclinical activities for their lead asset, Probudur. The operating loss for the quarter was $3.5 million, compared to $3.1 million in 2023. As of June 30, 2024, Virpax had cash reserves of approximately $1.9 million. The company also highlighted recent developments, including positive results from a pharmacokinetics and safety study for Probudur, securing $2.8 million from warrant exercises, and regaining compliance with Nasdaq's minimum bid price requirement. Additionally, Virpax completed a $2.5 million secured loan financing, which led to a reorganization of the company's Board of Directors and the repayment of litigation settlement liabilities.
總部位於特拉華州的Virpax製藥公司專業生產無成癮性疼痛管理和其他製藥產品。該公司於2024年8月13日公佈了截至同年6月30日的第二季度財務結果。該公司宣佈將總務和行政支出從去年同期的190萬美元減少到150萬美元,歸因於裁員和保險支出的減少。由於Probudur的臨床前活動,研發支出增加到200萬美元,比130萬美元增加。該季度的運營虧損爲350萬美元,2023年爲310萬美元。截至2024年6月30日,Virpax擁有大約190萬美元的現金儲備。此外,該公司還強調了最近的發展,包括Probudur的藥代動力學和安全研究獲得積極結果,從行權獲得280萬美元,以及重新符合納斯達克的最低買盤價格要求。此外,Virpax完成了250萬美元的抵押貸款融資,導致該公司董事會進行了重組並償還了訴訟和解的責任。
總部位於特拉華州的Virpax製藥公司專業生產無成癮性疼痛管理和其他製藥產品。該公司於2024年8月13日公佈了截至同年6月30日的第二季度財務結果。該公司宣佈將總務和行政支出從去年同期的190萬美元減少到150萬美元,歸因於裁員和保險支出的減少。由於Probudur的臨床前活動,研發支出增加到200萬美元,比130萬美元增加。該季度的運營虧損爲350萬美元,2023年爲310萬美元。截至2024年6月30日,Virpax擁有大約190萬美元的現金儲備。此外,該公司還強調了最近的發展,包括Probudur的藥代動力學和安全研究獲得積極結果,從行權獲得280萬美元,以及重新符合納斯達克的最低買盤價格要求。此外,Virpax完成了250萬美元的抵押貸款融資,導致該公司董事會進行了重組並償還了訴訟和解的責任。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。